We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
On May 15, we issued an updated research report on Myriad Genetics, Inc. (MYGN - Free Report) . The company is making significant progress as far as portfolio expansion is concerned. However, a tough competitive niche and pricing pressure might prove detrimental to Myriad’s stock in the near future. The stock carries a Zacks Rank #3 (Hold), at present.
Over the past six months, Myriad Genetics has underperformed the industry it belongs to. The stock plunged 42.3% against the industry’s 11.9% rise. Myriad Genetics exited third-quarter fiscal 2020 on a dull note, with earnings lagging the Zacks Consensus Estimate. While revenues beat the mark, the company saw a decline in operating segments due to the coronavirus outbreak.
Within Molecular Diagnostics, the majority of its test segments witnessed year-over-year revenue loss. The company experienced gross margin contraction due to escalation in costs and expenses and incurred operating loss during the quarter as well. Further, withdrawal of its guidance is concerning.
The top line, however, registered robust performance in the first two months of the quarter. EndoPredict testing boosted the top line and FDA approvals for myChoice CDx and BRACAnalysis CDx bode well. Potential in hereditary cancer testing instills optimism.
Once the coronavirus mayhem is over, Myriad Genetics expects to register an uptick in hereditary cancer volumes on account of its contract with UnitedHealthcare.
The company’s myPath Melanoma, which is in the preliminary stages of commercialization, has completed the first phase of the expanded launch and is being promoted to approximately 35% of the targeted market.
From a companion diagnostic perspective, the company witnessed significant progress with both BRACAnalysis CDx and myChoice CDx. In January 2020, the company submitted its application for BRACAnalysis CDx in castrate resistant metastatic prostate cancer, with the FDA approval anticipated to come in the latter half of fiscal 2020.
These developments are expected to result in a clinical impetus for patients of these two cancer types, including approximately 90,000 incident patients in the United States per year.
Meanwhile, Myriad Genetics faces acute competition in the key BRACAnalysis market. The company expects the same to intensify with newer advancements in this technology. We believe tough headwinds might reduce the prices of expensive tests provided by the company. This might, in turn, impede the stock’s margin improvement.
Key Picks
Some better-ranked stocks from the broader medical space are Aphria Inc. , Surmodics, Inc. (SRDX - Free Report) and Owens Minor, Inc. (OMI - Free Report) .
Surmodics’ long-term earnings growth rate is estimated at 10%. The company presently sports a Zacks Rank #1.
Owens Minor’s long-term earnings growth rate is estimated at 8.3%. It currently carries a Zacks Rank #2.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
Image: Bigstock
Myriad's (MYGN) EndoPredict Grows Amid Coronavirus Mayhem
On May 15, we issued an updated research report on Myriad Genetics, Inc. (MYGN - Free Report) . The company is making significant progress as far as portfolio expansion is concerned. However, a tough competitive niche and pricing pressure might prove detrimental to Myriad’s stock in the near future. The stock carries a Zacks Rank #3 (Hold), at present.
Over the past six months, Myriad Genetics has underperformed the industry it belongs to. The stock plunged 42.3% against the industry’s 11.9% rise. Myriad Genetics exited third-quarter fiscal 2020 on a dull note, with earnings lagging the Zacks Consensus Estimate. While revenues beat the mark, the company saw a decline in operating segments due to the coronavirus outbreak.
Within Molecular Diagnostics, the majority of its test segments witnessed year-over-year revenue loss. The company experienced gross margin contraction due to escalation in costs and expenses and incurred operating loss during the quarter as well. Further, withdrawal of its guidance is concerning.
The top line, however, registered robust performance in the first two months of the quarter. EndoPredict testing boosted the top line and FDA approvals for myChoice CDx and BRACAnalysis CDx bode well. Potential in hereditary cancer testing instills optimism.
Myriad Genetics, Inc. Price
Myriad Genetics, Inc. price | Myriad Genetics, Inc. Quote
Once the coronavirus mayhem is over, Myriad Genetics expects to register an uptick in hereditary cancer volumes on account of its contract with UnitedHealthcare.
The company’s myPath Melanoma, which is in the preliminary stages of commercialization, has completed the first phase of the expanded launch and is being promoted to approximately 35% of the targeted market.
From a companion diagnostic perspective, the company witnessed significant progress with both BRACAnalysis CDx and myChoice CDx. In January 2020, the company submitted its application for BRACAnalysis CDx in castrate resistant metastatic prostate cancer, with the FDA approval anticipated to come in the latter half of fiscal 2020.
These developments are expected to result in a clinical impetus for patients of these two cancer types, including approximately 90,000 incident patients in the United States per year.
Meanwhile, Myriad Genetics faces acute competition in the key BRACAnalysis market. The company expects the same to intensify with newer advancements in this technology. We believe tough headwinds might reduce the prices of expensive tests provided by the company. This might, in turn, impede the stock’s margin improvement.
Key Picks
Some better-ranked stocks from the broader medical space are Aphria Inc. , Surmodics, Inc. (SRDX - Free Report) and Owens Minor, Inc. (OMI - Free Report) .
Aphria has a projected long-term earnings growth rate of 24.6%. It currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Surmodics’ long-term earnings growth rate is estimated at 10%. The company presently sports a Zacks Rank #1.
Owens Minor’s long-term earnings growth rate is estimated at 8.3%. It currently carries a Zacks Rank #2.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>